QT prolongation – Page 6 – Communicable Diseases Research

Arrhythmias and COVID-19 A Review

Article

Published on 2020-08-102023-06-15
Journal: JACC. Clinical electrophysiology [Category] MERS, SARS,

PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial

Study Protocol

Published on 2020-07-312022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 24 hour addition Administered adverse event all subject allocation sequence Analysis antiviral activity Antiviral effect Arm arrhythmia Asymptomatic bradycardia can be used carried Cell Chronic kidney disease clinical Cluster Clusters Comorbidity Compliance conducted congestive heart failure Contact contraindication Coronaviruses covariates COVID-19 COVID-19 infection COVID-19 pandemic COVID-19 patient COVID-19 patients COVID-19 symptom Data monitoring committee database deficiency defined Department diabete diagnostic dialysis disease dissemination diuretics dose drug Drug-drug interactions during treatment early treatment Efficacy element eligible endosomal pH ENhance enrolled Epidemic Epidemiology equation EudraCT evaluate Evidence expected Factor female Final G6PD Generalized generate Glucose-6-phosphate glycosylation group Healthcare professional Hydroxychloroquine hydroxychloroquine/chloroquine identify in vitro in vivo inclusion criteria independent index index case index cases Infection interim analysis involved IRCCS ischemic heart disease Italian region Italy Loading dose male malignancy medication mental illness mild symptoms neurological number objective observation open label oropharyngeal swab outcome parallel group participant Patient patients with COVID-19 Paucisymptomatic performed positive PCR test Prevent prevention prevention of COVID-19 Prophylaxis proportion Proteins protocol protocol amendment Public QT prolongation randomization Randomized Randomized controlled clinical trial Randomized controlled trial reached receive recorded recruited reduced reduction in Registered reported required risk Sample size SARS-CoV-2 shown Standard status stratified Studio Study protocol subject subjects Support Swab Symptom symptomatic syndrome Tablet therapeutic approaches therapy Toxicity treat treated Treatment Trial trial protocol ventricular viral surface virus virus infection website with COVID-19
[DOI] 10.1186/s13063-020-04527-4 PMC 바로가기 [Article Type] Study Protocol

Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis

Medicine

Published on 2020-07-292022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] 95% CI Administered adverse event adverse events aminoquinoline anti-malarial drug Anti-malarial drugs arrhythmia Azithromycin cardiac event carried Chloroquine clinical trial Combination coronavirus COVID-19 COVID-19 infection database drug ECG Effect Efficacy eight evaluated Evidence Evidence-based medicine Good HCQ Hospitalized Hydroxychloroquine In-vitro increased risk Infection inhibit laboratory parameter Major material Meta-analysis Mortality no significant effect non-randomized trial observational studies OSF outcome outcome measure pandemic participant Participants patients Primary outcome provided QT prolongation RCT reached Registration required review risk Safety SARS-CoV-2 secondary significantly increased systematic review Treatment with COVID-19
[DOI] 10.3389/fmed.2020.00482 PMC 바로가기 [Article Type] Medicine

Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease

Research Article

Published on 2020-07-232022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS, SARS,

[키워드] Abnormalities abnormality appear Arrhythmias assessment baseline Blood caused changes in Clinical data Clinical outcome coronavirus 2019 disease coronavirus disease Course COVID-19 diarrhea died dose evaluate failure grade 3 HCQ HCQ therapy highlighting Hospitalization hospitalized patient hospitals Hydroxychloroquine hypoxia IMPROVE in vitro activity in-hospital mortality incident liver mechanical ventilation New York City occurred outcomes Patient proportion QT prolongation randomized trials receiving requiring supplemental oxygen Respiratory Coronavirus Result retrospective cohort study Safe Safety SARS-CoV-2 supplemental oxygen sustained therapy Tolerability tolerable Treatment ventricular vomiting with COVID-19 worldwide pandemic
[DOI] 10.1371/journal.pone.0236778 PMC 바로가기 [Article Type] Research Article

Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial

Letter

Published on 2020-07-092022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 absence Admission allergy alteration Antibody test anticipated Antigen approved assigned blinded breast-feeding Burgos Cancer chronic liver disease cirrhosis clearance clinical clinical symptom clinical trial Complete Corticosteroid Course COVID-19 COVID19 creatinine criteria delirium Department Desaturation Deterioration diabete Diagnosis dissemination drug Dyspnea Early pulmonary early stage Effectiveness element Emergency EudraCT evaluate exclusion for inclusion glucocorticoid greater group heart hidden history HIV infection hospital Hospital admission Hospital stay Hydroxychloroquine hypertension ICU admission Immunosuppression immunosuppressive include Inclusion intention-to-treat basis interactions Intervention local Ethics Committee lung lung involvement meet mild pneumonia modify number objective observation Occurrence Other other diseases outcome Outpatient outpatients Paracetamol parallel group participant Participation Patient patients’ medical records PCR per protocol performed physician Pneumonia power of 80% Prednisone professionals protocol pulmonary involvement QT prolongation radiological random randomised randomised controlled trial Randomized receive recruitment reduce reflected Registered renal responsible risk Sample size SARS-COV-2 infection sealed secondary sequence Spain Spanish status steroid Steroids stratified Stratified randomization study drug study inclusion subject Symptom the patient Treatment Trial verbal website women X-ray
[DOI] 10.1186/s13063-020-04575-w PMC 바로가기 [Article Type] Letter

Posicionamento para Ressuscitação Cardiopulmonar de Pacientes com Diagnóstico ou Suspeita de COVID-19 – 2020

Posicionamento

Published on 2020-06-292022-10-28
Journal: Arquivos Brasileiros de Cardiologia [Category] Coronavirus, SARS,

[키워드] addressed AHA airway AmB American Heart Association Anesthesiology Cardiac arrhythmia Cardiology Cardiopulmonary cardiovascular Care cause Chest Committee coronavirus disease COVID-19 Dada deviate Emergency Evidence guideline Health care worker HEPA HEPA filter hypoxia imperative include individual International invasive joint mandatory mechanical ventilation Medicine myocarditis National Pandemia pandemic Patient patient population Personal protective equipment precautions prone positioning protocol provide QT prolongation recommendation representing Resuscitation robust Society unique ventilator
[DOI] 10.36660/abc.20200548 PMC 바로가기 [Article Type] Posicionamento

A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation

Article

Published on 2020-06-152022-10-30
Journal: Journal of Clinical Medicine [Category] COVID-19,

[키워드] 95% confidence interval adverse event Adverse reaction AEs Analysis analyzed Arrhythmias Atrioventricular block authorization calculate cardiac cardiac dysfunction Cardiomyopathy cardiovascular adverse events clinical benefits Clinical studies clinical study clinical trial Complete coronavirus disease COVID-19 database dataset determine diastolic drug dysfunction Effectiveness Efficacy Ejection fraction Emergency EUA FDA feasible food HCQ High dose higher risk highlight Hospitalized Hydroxychloroquine investigated Mitigation non-randomized Odds ratio outcome Patient patients performed pharmacovigilance pharmacovigilance analysis Potential predict QT prolongation Randomized Reactions receiving reported robust Safety subsequent therapy torsades de pointe torsades de pointes treatment regimen ventricular was used widespread with COVID-19
[DOI] 10.3390/jcm9061867 PMC 바로가기 [Article Type] Article

Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network

Practice guideline

Published on 2020-06-012022-10-05
Journal: Revue neurologique [Category] SARS, 유전자 메커니즘,

[키워드] absence acute respiratory syndrome adaptation Administered Admission adopted Affect asked assessment cardiorespiratory Care caused concerning conditions coronavirus COVID-19 COVID-19 pandemic COVID-19 treatments criteria Degradation detrimental diagnostic Diseases eligible FAQ France French Guidance guidelines homogenize Hospitalization ICU implementation intensive care limit management manifestation measure National network Neuromuscular neuromuscular disease NIV Noninvasive ventilation outbreak pathology Patient patients patients treated positive Prognosis provided QT prolongation question risk SARS-CoV-2 Support survival the epidemic the patient Treatment website
[DOI] 10.1016/j.neurol.2020.04.004 [Article Type] Practice guideline

Cardiovascular disease management during the coronavirus disease 2019 pandemic

Review

Published on 2020-05-292022-10-29
Journal: International Journal of Medical Sciences [Category] COVID-19, MERS,

Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria

아프리카의 비복합형 팔시파룸 말라리아 환자에서 피페라퀸의 심혈관 안전성 및 인구 약리학적 특성에 대한 다기관 집합 분석

Article

Published on 2020-04-202024-08-11
Journal: Med Instrum [Category] 말라리아,

[키워드] antimalarial agents cardiovascular safety malaria Piperaquine population pharmacokinetic-pharmacodynamic model Population pharmacokinetics QT prolongation
[DOI] 10.1128/AAC.01848-19 PMC 바로가기